/Amx-883, a potent and selective degrader of BRD9 drives differentiation in acute myeloid leukaemia and shows synergistic efficacy in combination with venetoclax In Vivo and prevents the emergence of resistance to venetoclax in vitro.
Article

Amx-883, a potent and selective degrader of BRD9 drives differentiation in acute myeloid leukaemia and shows synergistic efficacy in combination with venetoclax In Vivo and prevents the emergence of resistance to venetoclax in vitro.

November 3, 2025
Blood
DOI:10.1182/blood-2025-1489
Citation Map
The articles shown here are a subset.See the full list of articles below.

Citing (0)

Data not found

Cited By (0)